Quick Facts: Uses of Prepulsid

• Relief of Heartburn: Used for the management of nocturnal heartburn.
• Gastroesophageal Reflux Disease (GERD): Indicated for the symptomatic treatment of adult patients with GERD.
• Gastric Motility: Promotes the movement of contents through the digestive system.

---

Prepulsid (cisapride) is a prescription medicine primarily indicated for the symptomatic treatment of nocturnal heartburn in adults with gastroesophageal reflux disease (GERD). Nocturnal heartburn is a specific symptom that occurs when stomach contents return to the esophagus, which can be more frequent when lying down. The drug is generally reserved for patients who have not experienced adequate symptom relief from adjustments to lifestyle and standard acid-reducing medicines.

The main benefit of Prepulsid is its action in the upper gastrointestinal tract. It works to increase the strength of the muscular contractions in the esophagus and stomach, which helps to increase lower esophageal sphincter pressure and accelerate the movement of food from the stomach to the intestines. This action can contribute to the clearance of acid from the esophagus, which is associated with the reduction of heartburn symptoms. Due to the potential for serious cardiac adverse effects, the use of this medicine has been significantly restricted globally.

Prepulsid has also been studied for other conditions involving delayed gastric emptying or motility disorders, such as gastroparesis, but its primary established indication is the relief of nocturnal heartburn symptoms related to GERD.

Prepulsid (cisapride) is subject to strict regulatory control, with eligibility defined primarily by absolute prohibitions due to the risk of serious cardiac arrhythmias. The medicine is reserved only for adult patients with symptomatic Gastroesophageal Reflux Disease (GERD) who have failed other standard therapies.

Category	Eligibility Rule
Absolute Contraindications	Prohibited for patients with a history of cardiac arrhythmias, congenital long QT syndrome, heart failure, ischemic heart disease, or clinically significant bradycardia [FDA Label].
	Prohibited in the presence of uncorrected electrolyte disturbances (hypokalemia or hypomagnesemia) or conditions like GI hemorrhage, obstruction, or perforation.
	Prohibited when co-administered with CYP3A4 inhibitors (e.g., specific macrolide antibiotics, antifungals) or other QT-prolonging drugs.
Age-Related	The safety and effectiveness in children younger than 16 years have not been established; pediatric use is generally prohibited. Use in older adults requires caution.
Organ Function	Caution and potential dose reduction are required for patients with hepatic or severe renal impairment.
Pregnancy/Lactation	Not recommended during pregnancy or breastfeeding, as documented by regulatory agencies [EMA SmPC].

These official statements strictly define who cannot use the drug, focusing on the exclusion of any patient with underlying cardiac vulnerabilities or conditions that increase drug exposure.

Interactions with other medicines and products

The use of Prepulsid (cisapride) with other medicines and products is governed by two primary concerns documented in official regulatory labeling: significant elevation of cisapride plasma levels and additive effects on the heart's electrical rhythm.

---

Contraindicated Combinations

Co-administration with the following drug categories is strictly forbidden due to the risk of serious ventricular arrhythmias, including Torsades de Pointes:

• Potent CYP3A4 Inhibitors: Medicines that inhibit the primary enzyme metabolizing cisapride, such as azole antifungals (e.g., ketoconazole, itraconazole) and macrolide antibiotics (e.g., erythromycin, clarithromycin).
• QTc-Prolonging Agents: Other drugs known to prolong the cardiac QTc interval (e.g., Class IA and Class III antiarrhythmics).

---

Clinically Significant Interactions

Prepulsid's effect on gastrointestinal motility can alter the absorption of co-administered medicines, potentially necessitating dose adjustments. For example, the effects of oral anticoagulants like warfarin may require coagulation time monitoring upon starting or stopping cisapride. Cimetidine is documented to increase cisapride plasma levels. Furthermore, consumption of grapefruit juice is also contraindicated due to its CYP3A4 inhibitory action.

How Prepulsid Works

Prepulsid (cisapride) is a prokinetic agent whose mechanism of action is centered on modulating neural pathways to influence movement in the gastrointestinal tract.

---

Primary Action: Serotonin Receptor Agonism

The drug acts as a selective agonist on the 5-HT4 serotonin receptors found extensively in the enteric nervous system (ENS). Activation of these defined biological targets initiates a molecular cascade that increases the local release of the excitatory neurotransmitter, acetylcholine (ACh), which contributes to the modulation of signaling patterns in the gut.

---

Mechanistic Effect: Altered Gastrointestinal Transit

This enhanced release of acetylcholine strengthens the signaling dynamics within the myenteric plexus, which controls the muscle contractions of the bowel wall. This modification promotes cholinergic neurotransmission, leading to changes in the signaling sequences that govern propulsive movement. The result is the direct enhancement of muscle contraction strength and coordination, which is defined as a prokinetic effect. This activity alters the rate of gastric emptying and influences the passage of material through the small and large intestines.

The administration of Prepulsid (cisapride) is restricted due to the potential for serious cardiac arrhythmias, including Torsades de Pointes. Strict adherence to instructions is mandatory for use in adult patients who meet specific clinical criteria via a limited-access protocol.

Official Administration Guidelines

Administration Scope	Instructions
Route of Administration	Oral (tablet or suspension)
Dosing Schedule	10 mg four times daily, taken 15 minutes before meals and at bedtime. The dosage may be increased to 20 mg per dose if clinically necessary.
Hepatic Impairment	The total daily dose must be reduced by 50% in patients with hepatic insufficiency.
Missed Dose	If a dose is forgotten, do not take the missed dose. Take the next dose at the regularly scheduled time. Never take more than the prescribed dose at one time to compensate for a missed dose.

Mandatory Procedural Steps

Before initiating therapy, a 12-lead ECG must be performed, and treatment must not be started if the corrected QT interval (QTc) is found to exceed 450 milliseconds. Serum electrolytes (potassium, calcium, and magnesium) and creatinine levels must also be assessed before administration and whenever conditions arise that may affect electrolyte balance or renal function.

Patients should immediately stop taking Prepulsid and seek medical attention if they faint, feel dizzy, or experience a rapid or irregular heartbeat. Furthermore, grapefruit juice must be avoided at all times while on this therapy, as it can increase the drug's concentration in the blood. The safety and effectiveness in children younger than 16 years of age have not been established.

Research evidence / Overview of studies for Prepulsid

---

Gastroesophageal Reflux Disease (GERD)

Studies exploring the use of Prepulsid for conditions characterized by fluctuating or episodic manifestations like GERD have mainly been conducted in children and infants. These trials were designed to apply in studies examining patient-reported experiences and monitor physiological strain or stress, specifically by measuring outcomes related to systemic or functional imbalance, such as the amount of acid exposure in the esophagus.

Research examined how episodic or acute changes in acid reflux evolved during the study period. Some trials comparing Prepulsid to an inactive treatment (placebo) or other non-surgical approaches reported that research highlights changes measured during the study period, indicating that for some patients, the time the esophagus was exposed to acid was observed to change significantly. However, this measured change in the amount of acid may not always have corresponded to a clear or statistically significant change in the visible symptoms reported by patients, such as vomiting or regurgitation. In other words, while the studies monitored a physiological change, the impact on patient-reported outcomes describing perceived discomfort was mixed.

The evidence is limited for definitive conclusions about whether the use of Prepulsid was associated with changes in outcomes related to physical discomfort like vomiting and esophagitis (inflammation of the esophagus) when compared to other non-surgical treatments. Findings were mixed across different studies, and some analyses suggested that there was no proof that Prepulsid was associated with changes in the symptoms of GERD. The overall quality and consistency of the evidence in this area varies across studies, and some analyses raised doubts because the results were so different between the trials conducted.

---

Gastroparesis

Studies for gastroparesis, a condition marked by functional limitations often related to delayed stomach emptying, were primarily designed as trials to evaluate how the drug was studied in relation to the movement of food out of the stomach, and how this related to outcomes related to physical discomfort like vomiting and nausea. This research was applied in research contexts involving fluctuating or unstable symptoms for patients, including those with diabetes.

Research explored the relationship between Prepulsid and the time it takes for the stomach to empty, which is a key measure of the condition. Some meta-analyses (studies that combine data from multiple trials) suggest that when Prepulsid was used, research examined the relationship between Prepulsid and gastric emptying time, and changes were observed in some studies. This research highlights changes measured during the study period, indicating that the time observed for stomach emptying was observed to change in some studies. Findings also indicate patterns observed in the studies related to some patient-reported outcomes describing perceived discomfort.

However, research limitations exist, particularly when evaluating its long-term effects. For patients with gastroparesis related to diabetes, some trials exploring short-term symptom changes did not find a significant difference from placebo regarding overall patient-reported effects on symptoms. While some studies observed a change in stomach motility, the severity of the symptoms may not always have correlated with the measured changes in stomach emptying. The evidence for Prepulsid in severe or "end-stage" gastroparesis remains insufficient, and evidence for long-term outcomes is not fully established.

---

Non-Ulcer Dyspepsia (NUD) / Functional Dyspepsia

For conditions where symptoms may vary in intensity such as NUD, studies were conducted during periods of increased symptom activity and focused on outcomes related to physical discomfort like upper abdominal pain, bloating, and early fullness after eating. These studies explored whether Prepulsid was associated with changes in symptoms compared to an inactive treatment or other medications.

The evidence suggests that in various trials, data show patterns related to Prepulsid compared to an inactive treatment. Specifically, data show patterns related to changes in symptoms like epigastric pain and early satiety in some cohorts. In small-scale, short-term trials, Prepulsid was studied in some cohorts where other medications were also observed to manage similar outcomes reflecting daily functioning or activity level.

However, the findings were mixed when trying to reach a definitive conclusion. Some studies found that while initial change was noted after a short period (such as two weeks), the monitored change may not persist after a longer period (such as four weeks). A large multicenter study did not find a statistically significant difference in patient symptom change between Prepulsid and placebo over a six-week period. This significant difference in results between studies highlights that certainty remains low for this indication. Subgroup findings are uncertain, as the large variability in how patients were selected across the trials makes it challenging to interpret the overall results.

Key Studies & References

1. Use of cisapride in patients with non-ulcer dyspepsia: a meta-analysis of randomized trials (Cochrane Review)
2. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility

Common questions about Prepulsid (FAQ)

---

Q: What are the most common side effects of Prepulsid?

Official product information, based on clinical trials, indicates that the most common adverse reactions reported were related to the digestive system. These included diarrhea or loose stools and abdominal cramping. Headache was also a frequently reported symptom.

---

Q: How long does it takes for Prepulsid to start working?

Studies included in the official product information suggest that the therapeutic effect of cisapride generally begins within 0.5 to 1 hour after oral administration. This represents the reported time required for the drug's activity to begin affecting the digestive tract.

---

Q: What should I do if I experience a rapid heartbeat while on Prepulsid?

Official regulatory information emphasizes that if fainting, dizziness, or a rapid or irregular heartbeat is experienced, the medication should be immediately stopped. Seeking immediate medical attention or calling emergency services is advised if these symptoms are experienced, especially if they are severe.

---

Q: How do I safely dispose of unused Prepulsid?

When disposing of the medication bottles or containers, it is advised to remove or permanently obscure any personal identifying information from the prescription label. This is done to protect identity and prevent misuse of the empty container.

---

Q: Is Prepulsid a controlled substance?

Cisapride is not classified as a scheduled controlled substance under the U.S. Controlled Substances Act. However, its use is strictly limited by the FDA to a special access program because of potential serious safety risks.

---

Q: Can I drink alcohol while taking Prepulsid?

Official drug labeling indicates that cisapride may increase or accelerate the effects that alcohol has on the body. The official labeling advises consulting with a healthcare provider to discuss any potential risks associated with consuming alcohol during this treatment.

---

Q: What conditions specifically cause the restricted access protocol for Prepulsid?

The FDA's Limited Access Program restricts the use of Prepulsid to adult patients with severe conditions who have not found relief with other treatments. These conditions typically include severe Gastroesophageal Reflux Disease (GERD), gastroparesis, intestinal pseudo-obstruction, and severe chronic constipation.

Prepulsid (cisapride) must be stored and handled according to specific conditions defined in the official regulatory labeling.

Official Storage Conditions

Prepulsid tablets and oral suspension require storage at Controlled Room Temperature, which is defined as 15 C to 25 C (59 F to 77 F). The tablets must be protected from moisture, and the 20 mg tablets specifically require protection from light to maintain stability. The medicine must always be kept out of the reach and sight of children.

Disposal Instructions

When discarding unused or expired Prepulsid, the primary official recommendation is to utilize a drug take-back program if one is available. If a take-back program cannot be accessed, the medicine can be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a container, and disposed of in the household trash. Prepulsid is not classified as a medicine that should be flushed down the toilet or sink.